European Software Industry helps fund research to cure Parkinson’s
Cure Parkinson’s is delighted to announce that it has been chosen as the official charity partner to Boardwave supporting Parkinson’s research.
Cough medicine offers hope of new treatment to slow the progression of Parkinson’s disease
10 January 2023 Following promising results reported at Phase 2 in 2020, a large-scale Phase 3 clinical trial of ambroxol, a drug currently in use to treat respiratory conditions, will start in early 2023. The ASPro-PD trial is a world-first Phase 3 trial aimed at…
Cure Parkinson’s announces new role: Head of Pipeline Research
13 October 2022 Cure Parkinson’s is delighted to announce that Dr Leah Mursaleen has been appointed to the newly created role, Head of Pipeline Research. The purpose of this role is to speed up and drive forward early-stage research to ensure that novel treatments for…
2022 Tom Isaacs Award honours leading Parkinson’s researchers and co-authors of Ending Parkinson’s
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Ray Dorsey, the David Levy Professor of Neurology at the University of Rochester, and Dr Michael Okun, Chair and the Adelaide Lackner Professor of Neurology at the University of Florida, as joint winners…
Professor David K. Simon announced as new chair of leading Parkinson’s research committee
27 September 2022 Cure Parkinson’s and Van Andel Institute are delighted to announce that Professor David K. Simon, of Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States has accepted the position as chair of the International Linked Clinical Trials (iLCT) Committee….